Kane Biotech, Inc. (KNE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

NexgenRx, Inc.

Everyday People Financial Corp.

Willow Biosciences, Inc.

Kane Biotech, Inc.

American Aires, Inc.

Personas Social, Inc.

TDG Gold Corp.

SOL Global Investments Corp.

RevoluGROUP Canada, Inc.

ASEP Medical Holdings, Inc.

NextGen Food Robotics Corp.

Why is Kane Biotech, Inc. ?

Flat results in Mar 25

NET PROFIT(Q) At CAD -1.22 MM has Fallen at -54.19%
OPERATING PROFIT(Q) Lowest at CAD -1.22 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -75.00%, its profits have risen by 60.6%

Below par performance in long term as well as near term

Along with generating -75.00% returns in the last 1 year, the stock has also underperformed S&P/TSX 60 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kane Biotech, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Kane Biotech, Inc.

-100.0%

-0.62

111.60%

S&P/TSX 60

19.1%

1.23

15.27%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.87%

EBIT Growth (5y)

3.94%

EBIT to Interest (avg)

-4.63

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.75

Sales to Capital Employed (avg)

-0.45

Tax Ratio

31.23%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-5.50

EV to EBIT

-1.70

EV to EBITDA

-1.81

EV to Capital Employed

5.79

EV to Sales

3.13

PEG Ratio

Dividend Yield

ROCE (Latest)

-340.12%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -91.78% (YoY

-4What is not working for the Company

NET PROFIT(Q)

At CAD -1.22 MM has Fallen at -54.19%

OPERATING PROFIT(Q)

Lowest at CAD -1.22 MM

Here's what is working for Kane Biotech, Inc.

Raw Material Cost

Fallen by -91.78% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Kane Biotech, Inc.

Net Profit

At CAD -1.22 MM has Fallen at -54.19%

over average net sales of the previous four periods of CAD -0.79 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CAD MM)

Operating Profit

Lowest at CAD -1.22 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CAD MM)